Shanghai, November 18th, 2019, Elpiscience Biopharma, Ltd., a clinical-stage immuno-oncology company, announced the appointment of Dr. Robert H. Arch as Senior Vice President, Head of Research.
A skilled drug hunter with a doctorate in immunology and cell biology, Dr. Arch has over 23 years of expertise with in vitro and in vivo models, pharmacology and biomarkers for small and large molecule approaches. Prior to Elpisicience, Dr. Arch served as Executive Director of Novartis Institute for Biomedical Research in China. Before Novartis, he was a Senior Director at Takeda Pharmaceuticals, Inc. in the U.S and held positions of increasing seniority at Pfizer and GlaxoSmithKline. Dr. Arch earned his Ph.D. from the Julius Maximillian University of Wuerzburg, Germany, and received postdoctoral training at the German Cancer Research Center in Heidelberg, Germany, and the University of Chicago, USA. He went on to successfully establish his own research laboratory at Washington University, Saint Louis, USA. Dr. Arch has published extensively in the fields of T cell biology, cancer metastasis, and signal transduction in immune cells to delineate the role of the immune system in health and disease. This led him to pursue his passion for drug hunting in Research and Development in the pharmaceutical and biotechnology industry.
Dr. Hongtao Lu, Co-Founder, and CSO of Elpiscience: “We are very excited to have Dr. Arch joining us. Dr. Arch is a trained immunologist and an industry veteran with vast experience in drug discovery and development. He will take responsibilities in translational medicine and discovery biology platform at Elpiscience. Under his leadership, Elpiscience will expand the discovery capacity and translational medicine effort, significantly accelerating the growth of the company.”
Dr. Robert H. Arch: “Many people asked me why I decided to join Elpiscience out of many possibilities. In the short time since its inception, Elpiscience has already established a very impressive and competitive portfolio of innovative and diversified research and clinical-stage programs. I spent a large part of my academic career studying many of the same pathways and cells that Elpiscience is targeting. Therefore, I am convinced that some of these programs will provide very efficacious and novel treatment options for cancer patients in the future. Elpiscience is already well-recognized and on its path to becoming a leading company in the field of immuno-oncology in China and globally. It was no question that I wanted to be part of this future and hope my prior experiences will help the company to become successful and continue its growth.”
Elpiscience is a clinical-stage biopharmaceutical company focusing on cancer immunotherapy. The company is committed to becoming the gateway to cancer immunotherapy in China while striving to lead the development of next-generation cancer immunotherapies for the world.